Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PMGC Holdings Inc. stock logo
ELAB
PMGC
$1.14
-1.7%
$1.95
$1.11
$309.12
$1.32M-0.272.24 million shs315,099 shs
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$1.64
-1.8%
$1.36
$1.16
$7.20
$5.99M1.95112,282 shs27,450 shs
Soligenix Inc. stock logo
SNGX
Soligenix
$0.41
+3.8%
$0.59
$0.28
$6.23
$6.08M1.843.00 million shs642,483 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$1.12
-1.8%
$1.26
$0.85
$6.92
$5.36M1.29143,876 shs35,994 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PMGC Holdings Inc. stock logo
ELAB
PMGC
0.00%-17.99%-40.63%-31.74%-99.36%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.00%+12.33%+18.84%+20.59%-76.02%
Soligenix Inc. stock logo
SNGX
Soligenix
0.00%+2.63%-57.84%-63.72%-69.63%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00%-2.61%+0.90%-47.42%-60.84%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PMGC Holdings Inc. stock logo
ELAB
PMGC
$1.14
-1.7%
$1.95
$1.11
$309.12
$1.32M-0.272.24 million shs315,099 shs
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$1.64
-1.8%
$1.36
$1.16
$7.20
$5.99M1.95112,282 shs27,450 shs
Soligenix Inc. stock logo
SNGX
Soligenix
$0.41
+3.8%
$0.59
$0.28
$6.23
$6.08M1.843.00 million shs642,483 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$1.12
-1.8%
$1.26
$0.85
$6.92
$5.36M1.29143,876 shs35,994 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PMGC Holdings Inc. stock logo
ELAB
PMGC
0.00%-17.99%-40.63%-31.74%-99.36%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.00%+12.33%+18.84%+20.59%-76.02%
Soligenix Inc. stock logo
SNGX
Soligenix
0.00%+2.63%-57.84%-63.72%-69.63%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00%-2.61%+0.90%-47.42%-60.84%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
PMGC Holdings Inc. stock logo
ELAB
PMGC
1.00
SellN/AN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
1.00
SellN/AN/A
Soligenix Inc. stock logo
SNGX
Soligenix
2.00
Hold$6.001,363.41% Upside
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ELAB, SNGX, PULM, and SNOA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2026
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
Reiterated RatingSell (D-)
4/29/2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
DowngradeSell (D-)Sell (E+)
4/21/2026
Soligenix Inc. stock logo
SNGX
Soligenix
Reiterated RatingSell (E+)
(Data available from 6/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
PMGC Holdings Inc. stock logo
ELAB
PMGC
$590K2.24N/AN/A$93.33 per share0.01
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$7.81M0.77N/AN/A$2.45 per share0.67
Soligenix Inc. stock logo
SNGX
Soligenix
$120K50.64N/AN/A$0.52 per share0.79
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$19.53M0.27N/AN/A$0.65 per share1.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
PMGC Holdings Inc. stock logo
ELAB
PMGC
-$7.75M-$168.62N/AN/AN/AN/A-117.82%-70.79%N/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-$5.16M-$1.23N/AN/AN/AN/A-107.84%-91.58%8/12/2026 (Estimated)
Soligenix Inc. stock logo
SNGX
Soligenix
-$11.08M-$1.68N/AN/AN/AN/A-244.73%-131.22%8/13/2026 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.17M-$1.89N/AN/AN/A-16.26%-43.95%-11.27%7/15/2026 (Estimated)

Latest ELAB, SNGX, PULM, and SNOA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/15/2026N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.24N/AN/AN/A$5.57 millionN/A
6/16/2026Q4 2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.24-$0.33-$0.09-$0.33$5.57 million$5.56 million
5/15/2026Q1 2026
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A-$0.32N/A-$0.32N/AN/A
5/14/2026Q1 2026
PMGC Holdings Inc. stock logo
ELAB
PMGC
N/A-$11.2190N/A-$11.2190N/A$0.68 million
5/8/2026Q1 2026
Soligenix Inc. stock logo
SNGX
Soligenix
-$0.30-$0.28+$0.02-$0.28N/AN/A
3/30/2026Q4 2025
PMGC Holdings Inc. stock logo
ELAB
PMGC
N/A-$52.7570N/A-$52.7570N/A$0.30 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
PMGC Holdings Inc. stock logo
ELAB
PMGC
N/AN/AN/AN/AN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/AN/AN/AN/AN/A
Soligenix Inc. stock logo
SNGX
Soligenix
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
PMGC Holdings Inc. stock logo
ELAB
PMGC
0.03
1.45
1.43
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A
4.96
4.96
Soligenix Inc. stock logo
SNGX
Soligenix
N/A
1.81
1.81
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
2.50
1.75

Institutional Ownership

CompanyInstitutional Ownership
PMGC Holdings Inc. stock logo
ELAB
PMGC
22.22%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
11.84%
Soligenix Inc. stock logo
SNGX
Soligenix
3.60%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%

Insider Ownership

CompanyInsider Ownership
PMGC Holdings Inc. stock logo
ELAB
PMGC
0.01%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.62%
Soligenix Inc. stock logo
SNGX
Soligenix
3.05%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
2.29%
CompanyEmployeesShares OutstandingFree FloatOptionable
PMGC Holdings Inc. stock logo
ELAB
PMGC
181.16 million1.16 millionN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
203.65 million3.63 millionNot Optionable
Soligenix Inc. stock logo
SNGX
Soligenix
2014.82 million14.37 millionNot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1804.79 million4.68 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals reports higher revenue
Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMGC stock logo

PMGC NASDAQ:ELAB

$1.14 -0.02 (-1.72%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$1.14 0.00 (-0.44%)
As of 06/26/2026 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.

Pulmatrix stock logo

Pulmatrix NASDAQ:PULM

$1.64 -0.03 (-1.80%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$1.64 0.00 (-0.06%)
As of 06/26/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Soligenix stock logo

Soligenix NASDAQ:SNGX

$0.41 +0.02 (+3.80%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$0.40 -0.02 (-3.66%)
As of 06/26/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$1.12 -0.02 (-1.75%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$1.12 0.00 (0.00%)
As of 06/26/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.